10:01 AM EST - Oncolytics Biotech Inc : Today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel, for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma. This represents pelareorep's second FDA Fast Track designation. Oncolytics Biotech Inc
shares T.ONC are trading up $0.20 at $2.56.
